1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma

D. Schadendorf, R. Dummer,K.T. Flaherty, C. Robert,A.M. Arance Fernandez,J.W. de Groot, C. Garbe,H. Gogas, R. Gutzmer, I. Krajsova,G. Liszkay,C. Loquai, M. Mandalà,N. Yamazaki, C.A. Guenzel, A. Polli, M. Thakur,A. di Pietro,P.A. Ascierto

Annals of Oncology(2023)

引用 0|浏览2
暂无评分
关键词
v600–mutant melanoma,encorafenib,vemurafenib,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要